CClinicalTrials.gg
CompletedNCT02110888Updated Oct 18, 2021

Subcutaneous Peripheral Nerve Stimulation (PNS) as "Hybrid Stimulation" After Failure of Spinal Cord Stimulation (SCS) to Control the Back Pain Component in Failed Back Surgery Syndrome (FBSS) Patients.(CUMPNS Study)

An interventional study of Subcutaneous peripheral nerve stimulation and SCS Only in Failed Back Surgery Syndrome, sponsored by Poitiers University Hospital. Completed at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-10-18.

Sponsored by Poitiers University Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Feb 2013, registered Apr 2014).
Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Despite globally favourable outcomes of Spinal Cord Stimulation (SCS), a significant proportion of Failed Back Surgery Syndrome (FBSS) patients do not obtain adequate coverage of low back pain. Peripheral Nerve Stimulation (PNS) has obtained the European Conformity mark for the treatment of chronic refractory neuropathic pain and is now commonly used in some countries to target back pain. However, the potential value of combining SCS and PNS as "hybrid stimulation" remains poorly described with only isolated case reports or limited experience in various indications.

The "CUMPNS" comparative randomized study is designed to demonstrate the potential analgesic efficacy of PNS in addition to previously implanted SCS, to treat the residual low back pain component pain in refractory FBSS patients.

02

Conditions studied

  • Failed Back Surgery Syndrome
03

In context

Syndrome

9,221 studies on the registry are indexed under Syndrome; 1,034 are open to participants now.

This study's enrollment of 14 is below the median of 50 across 6,517 interventional studies indexed under Syndrome.

Browse Syndrome studies →

Lead sponsor

Poitiers University Hospital is the lead sponsor of 310 studies on the registry; 64 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age ≥ 18 years and ≤ 80 years.
  • History of FBSS after one or more surgical procedures on the spine, treated with SCS,
  • Failure of well conducted conservative treatment (drug or non-drug).
  • Patients implanted with a single-column or multicolumn SCS lead providing significant relief of the radicular pain component.
  • Persistent failure on the low back pain component despite the efficacy of SCS on the radicular pain component.
  • Patients with documented residual neuropathic low back pain (DN4, sensorimotor studies, clinical examination, pain characteristics, etc.).
  • Patients with significant residual low back pain with mean intensity on Visual Analogue Scale (VAS) ≥ 40 mm) despite Conventional Medical Management (CMM) and SCS (mean measure calculated on daily VAS scores on 5 consecutive days).
  • Positive response to Transcutaneous Electrical Nerve Stimulation (TENS) trial on the back pain component.
  • Patients understanding and accepting the study constraints.
  • Patients covered by French national health insurance.
  • Patients have signed the Informed Consent Form after being provided with clear and honest information about the study.
  • Absence of active psychosis or serious psychotic history requiring hospitalisation.
  • Absence of active cancer.

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years and > 80 years.
  • Back pain amenable to further aetiological biomechanical surgery (discogenic pain, spinal instability, spinal deformity, etc.).
  • Surgical, psychiatric or anaesthetic contraindication to PNS lead implantation.
  • Negative response to TENS trial.
  • Absence of signature of the informed consent form.
  • Patients not covered by French national health insurance.
  • Subjects requiring closer protection, i.e. minors, pregnant women, nursing mothers, subjects deprived of their freedom by a court or administrative decision, subjects admitted to a health or social welfare establishment, major subjects under legal protection, and finally patients member of a high-risk population.
  • Women of childbearing age not using effective contraception.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    SCS + PNS

    Mutlticolumn SCS lead + Monocolumn SCS lead

    Device: Subcutaneous peripheral nerve stimulation

  • Active comparator
    SCS

    Mutlticolumn SCS lead

    Other: SCS Only

Interventions

  • DeviceSubcutaneous peripheral nerve stimulation
  • OtherSCS Only
06

What researchers measure

Primary outcomes

  1. Relative change of low back pain surface (expressed as a percentage, %)

    Time frame: 3 month follow-up

07

Study locations

1 site
  • Poitiers University Hospital
    Poitiers, 86021, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02110888
Lead sponsor
Poitiers University Hospital
Responsible party
Sponsor
First posted
Apr 10, 2014
Start date
Feb 2013
Primary completion
Oct 14, 2018
Completion
Oct 14, 2018
Last update
Oct 18, 2021

Study contacts

Philippe RIGOARD, MD, PhD
principal investigator · Poitiers University Hospital
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion